{"id":"https://openalex.org/W3019885136","doi":"https://doi.org/10.1097/mol.0000000000000679","title":"The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease?","display_name":"The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease?","alternate_titles":[],"publication_year":2020,"publication_date":"2020-04-23","ids":{"openalex":"https://openalex.org/W3019885136","doi":"https://doi.org/10.1097/mol.0000000000000679","mag":"3019885136","pmid":"https://pubmed.ncbi.nlm.nih.gov/32324598"},"language":"en","primary_location":{"id":"doi:10.1097/mol.0000000000000679","doi":"https://doi.org/10.1097/mol.0000000000000679","is_oa":true,"landing_page_url":"https://doi.org/10.1097/mol.0000000000000679","pdf_url":null,"source":{"id":"https://openalex.org/S203964698","display_name":"Current Opinion in Lipidology","issn_l":"0957-9672","issn":["0957-9672","1473-6535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Opinion in Lipidology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W3019885136"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1097/mol.0000000000000679","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5075154354","display_name":"Laurens F. Reeskamp","orcid":"https://orcid.org/0000-0002-8043-951X","observed_orcids":["https://orcid.org/0000-0002-8043-951X"]},"institutions":[{"id":"https://openalex.org/I4210151833","display_name":"Amsterdam University Medical Centers","ror":"https://ror.org/05grdyy37","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I4210151833"]}],"countries":["NL"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Laurens F. Reeskamp","raw_affiliation_strings":["Department of Vascular Medicine, Amsterdam UMC, Amsterdam, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Vascular Medicine, Amsterdam UMC, Amsterdam, The Netherlands","institution_ids":["https://openalex.org/I4210151833"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036726564","display_name":"Tycho R. Tromp","orcid":"https://orcid.org/0000-0001-8107-827X","observed_orcids":["https://orcid.org/0000-0001-8107-827X"]},"institutions":[],"countries":[],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Tycho R. Tromp","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5081557648","display_name":"Erik S.G. Stroes","orcid":"https://orcid.org/0000-0001-9555-6260","observed_orcids":["https://orcid.org/0000-0001-9555-6260","https://orcid.org/0009-0000-7584-7677"]},"institutions":[{"id":"https://openalex.org/I2802928900","display_name":"Amsterdam UMC Location University of Amsterdam","ror":"https://ror.org/03t4gr691","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2802928900","https://openalex.org/I4210151833"]},{"id":"https://openalex.org/I4210151833","display_name":"Amsterdam University Medical Centers","ror":"https://ror.org/05grdyy37","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I4210151833"]}],"countries":["NL"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Erik S.G. Stroes","raw_affiliation_strings":["Department of Vascular Medicine, Amsterdam UMC, Amsterdam, The Netherlands","to Erik S.G. Stroes, Department of Vascular Medicine, Amsterdam UMC, Meibergdreef 9, Room D3-330, 1100 AZ Amsterdam, The Netherlands. Tel: +31 20 5628287; e-mail: [email\u00a0protected]","e-mail: [email\u00a0protected]","to Erik S.G. Stroes, Department of Vascular Medicine, Amsterdam UMC, Meibergdreef 9, Room D3-330, 1100 AZ Amsterdam, The Netherlands. Tel: +31 20 5628287"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Vascular Medicine, Amsterdam UMC, Amsterdam, The Netherlands","institution_ids":["https://openalex.org/I4210151833"]},{"raw_affiliation_string":"to Erik S.G. Stroes, Department of Vascular Medicine, Amsterdam UMC, Meibergdreef 9, Room D3-330, 1100 AZ Amsterdam, The Netherlands. Tel: +31 20 5628287; e-mail: [email\u00a0protected]","institution_ids":["https://openalex.org/I2802928900","https://openalex.org/I4210151833"]},{"raw_affiliation_string":"e-mail: [email\u00a0protected]","institution_ids":[]},{"raw_affiliation_string":"to Erik S.G. Stroes, Department of Vascular Medicine, Amsterdam UMC, Meibergdreef 9, Room D3-330, 1100 AZ Amsterdam, The Netherlands. Tel: +31 20 5628287","institution_ids":["https://openalex.org/I4210151833"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5036726564","https://openalex.org/A5075154354"],"corresponding_institution_ids":["https://openalex.org/I4210151833"],"apc_list":null,"apc_paid":null,"fwci":1.2722,"has_fulltext":true,"cited_by_count":40,"citation_normalized_percentile":{"value":0.8094028,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":92,"max":99},"biblio":{"volume":"31","issue":"3","first_page":"140","last_page":"146"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T13430","display_name":"Lipid metabolism and disorders","score":0.8637999892234802,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T13430","display_name":"Lipid metabolism and disorders","score":0.8637999892234802,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.13490000367164612,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10027","display_name":"Diabetes, Cardiovascular Risks, and Lipoproteins","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/apolipoprotein-c-iii","display_name":"apolipoprotein C-III","score":0.9919999837875366},{"id":"https://openalex.org/keywords/angptl3","display_name":"ANGPTL3","score":0.9739999771118164},{"id":"https://openalex.org/keywords/triglyceride-lowering-drugs","display_name":"triglyceride-lowering drugs","score":0.824999988079071},{"id":"https://openalex.org/keywords/triglyceride-metabolism","display_name":"triglyceride metabolism","score":0.9259999990463257},{"id":"https://openalex.org/keywords/cardiovascular-disease-risk-reduction","display_name":"cardiovascular disease risk reduction","score":0.8149999976158142},{"id":"https://openalex.org/keywords/apolipoprotein-b","display_name":"apolipoprotein B","score":0.765999972820282},{"id":"https://openalex.org/keywords/volanesorsen","display_name":"volanesorsen","score":0.8259999752044678},{"id":"https://openalex.org/keywords/antisense-therapy","display_name":"antisense therapy","score":0.7649999856948853},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.902999997138977},{"id":"https://openalex.org/keywords/triglyceride-rich-lipoproteins","display_name":"triglyceride-rich lipoproteins","score":0.847000002861023},{"id":"https://openalex.org/keywords/dyslipidemia","display_name":"dyslipidemia","score":0.8410000205039978},{"id":"https://openalex.org/keywords/mendelian-randomization","display_name":"Mendelian randomization","score":0.7080000042915344}],"concepts":[{"id":"https://openalex.org/C62746215","wikidata":"https://www.wikidata.org/wiki/Q14890615","display_name":"Apolipoprotein B","level":3,"score":0.7177678346633911},{"id":"https://openalex.org/C2778913445","wikidata":"https://www.wikidata.org/wiki/Q186319","display_name":"Triglyceride","level":3,"score":0.6725917458534241},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5087648034095764},{"id":"https://openalex.org/C13028836","wikidata":"https://www.wikidata.org/wiki/Q21122998","display_name":"Microsomal triglyceride transfer protein","level":5,"score":0.5075844526290894},{"id":"https://openalex.org/C2780072125","wikidata":"https://www.wikidata.org/wiki/Q28350","display_name":"Lipoprotein","level":3,"score":0.4696606397628784},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.44623783230781555},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.43279343843460083},{"id":"https://openalex.org/C57089818","wikidata":"https://www.wikidata.org/wiki/Q424728","display_name":"Apolipoprotein E","level":3,"score":0.4236224293708801},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.41419684886932373},{"id":"https://openalex.org/C2778163477","wikidata":"https://www.wikidata.org/wiki/Q43656","display_name":"Cholesterol","level":2,"score":0.3932105004787445},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.33617717027664185},{"id":"https://openalex.org/C8243546","wikidata":"https://www.wikidata.org/wiki/Q419074","display_name":"Very low-density lipoprotein","level":4,"score":0.17401224374771118}],"mesh":[{"descriptor_ui":"D000075802","descriptor_name":"Angiopoietin-like Proteins","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D000075802","descriptor_name":"Angiopoietin-like Proteins","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D000091303","descriptor_name":"Angiopoietin-Like Protein 3","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014280","descriptor_name":"Triglycerides","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D014280","descriptor_name":"Triglycerides","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D014280","descriptor_name":"Triglycerides","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D015228","descriptor_name":"Hypertriglyceridemia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D015228","descriptor_name":"Hypertriglyceridemia","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D015228","descriptor_name":"Hypertriglyceridemia","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D016376","descriptor_name":"Oligonucleotides, Antisense","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D050356","descriptor_name":"Lipid Metabolism","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D053305","descriptor_name":"Apolipoprotein C-III","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D053305","descriptor_name":"Apolipoprotein C-III","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true}],"locations_count":4,"locations":[{"id":"doi:10.1097/mol.0000000000000679","doi":"https://doi.org/10.1097/mol.0000000000000679","is_oa":true,"landing_page_url":"https://doi.org/10.1097/mol.0000000000000679","pdf_url":null,"source":{"id":"https://openalex.org/S203964698","display_name":"Current Opinion in Lipidology","issn_l":"0957-9672","issn":["0957-9672","1473-6535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Opinion in Lipidology","raw_type":"journal-article"},{"id":"pmid:32324598","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/32324598","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current opinion in lipidology","raw_type":"Journal Article"},{"id":"pmh:oai:pure.amsterdamumc.nl:openaire/7f3fe7e2-40ed-48c9-9797-e69801807288","doi":null,"is_oa":true,"landing_page_url":"https://pure.amsterdamumc.nl/en/publications/7f3fe7e2-40ed-48c9-9797-e69801807288","pdf_url":null,"source":{"id":"https://openalex.org/S7407055222","display_name":"Pure Amsterdam UMC","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Reeskamp, L F, Tromp, T R & Stroes, E S G 2020, 'The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease?', Current opinion in lipidology, vol. 31, no. 3, pp. 140-146. https://doi.org/10.1097/MOL.0000000000000679","raw_type":"info:eu-repo/semantics/review"},{"id":"pmh:amcpub:oai:pure.amc.nl:publications/672818a9-0404-48e9-af8a-2f0b9f13d226","doi":null,"is_oa":true,"landing_page_url":"https://pure.amc.nl/en/publications/the-next-generation-of-triglyceridelowering-drugs-will-reducing-apolipoprotein-ciii-or-angiopoietin-like-protein-3-reduce-cardiovascular-disease(672818a9-0404-48e9-af8a-2f0b9f13d226).html","pdf_url":null,"source":{"id":"https://openalex.org/S4306401843","display_name":"Data Archiving and Networked Services (DANS)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1322597698","host_organization_name":"Royal Netherlands Academy of Arts and Sciences","host_organization_lineage":["https://openalex.org/I1322597698"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Current opinion in lipidology, 31(3), 140 - 146. Lippincott Williams and Wilkins","raw_type":"info:eu-repo/semantics/other"}],"best_oa_location":{"id":"doi:10.1097/mol.0000000000000679","doi":"https://doi.org/10.1097/mol.0000000000000679","is_oa":true,"landing_page_url":"https://doi.org/10.1097/mol.0000000000000679","pdf_url":null,"source":{"id":"https://openalex.org/S203964698","display_name":"Current Opinion in Lipidology","issn_l":"0957-9672","issn":["0957-9672","1473-6535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Opinion in Lipidology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":45,"referenced_works":["https://openalex.org/W2020915011","https://openalex.org/W2032456325","https://openalex.org/W2052644460","https://openalex.org/W2058804806","https://openalex.org/W2061100095","https://openalex.org/W2096210401","https://openalex.org/W2106937178","https://openalex.org/W2119276496","https://openalex.org/W2127427274","https://openalex.org/W2165200875","https://openalex.org/W2170009139","https://openalex.org/W2170210469","https://openalex.org/W2216998043","https://openalex.org/W2315899065","https://openalex.org/W2501649131","https://openalex.org/W2604768034","https://openalex.org/W2605659507","https://openalex.org/W2609543937","https://openalex.org/W2612663868","https://openalex.org/W2617605538","https://openalex.org/W2618984243","https://openalex.org/W2738009647","https://openalex.org/W2757794608","https://openalex.org/W2761312904","https://openalex.org/W2783047364","https://openalex.org/W2790564280","https://openalex.org/W2803101595","https://openalex.org/W2888943877","https://openalex.org/W2899669642","https://openalex.org/W2899689685","https://openalex.org/W2901156820","https://openalex.org/W2908761591","https://openalex.org/W2911290113","https://openalex.org/W2913161409","https://openalex.org/W2941139188","https://openalex.org/W2945023400","https://openalex.org/W2955013370","https://openalex.org/W2966503756","https://openalex.org/W2973983647","https://openalex.org/W2981767898","https://openalex.org/W2991262768","https://openalex.org/W3024028026","https://openalex.org/W6665519710","https://openalex.org/W6983295199","https://openalex.org/W7075706488"],"related_works":["https://openalex.org/W3134156560","https://openalex.org/W4317914558","https://openalex.org/W2793087028","https://openalex.org/W4313281055","https://openalex.org/W4391931703","https://openalex.org/W2508635189","https://openalex.org/W4376128675","https://openalex.org/W4303444510","https://openalex.org/W4389220157","https://openalex.org/W4391232753"],"abstract_inverted_index":{"PURPOSE":[0],"OF":[1],"REVIEW:":[2],"Apolipoprotein":[3],"C-III":[4],"(ApoC-III)":[5],"and":[6,57,62,90,94,145,187],"angiopoietin":[7],"like":[8],"protein":[9],"3":[10],"(angptl3)":[11],"have":[12],"emerged":[13],"as":[14],"key":[15],"regulators":[16],"of":[17,55,67,71],"triglyceride":[18,60,116,177],"metabolism.":[19],"Based":[20],"on":[21],"Mendelian":[22],"randomisation":[23],"studies,":[24,92],"novel":[25,148],"therapeutic":[26,74],"strategies":[27],"inhibiting":[28],"these":[29,72],"proteins":[30],"using":[31],"monoclonal":[32],"antibodies":[33],"or":[34,82],"gene":[35],"silencing":[36],"techniques":[37],"might":[38],"reduce":[39,154],"residual":[40],"cardiovascular":[41],"disease":[42],"(CVD)":[43],"risk":[44,161,211],"in":[45,59,118,137,150],"dyslipidemic":[46],"patients.":[47],"This":[48],"article":[49],"aims":[50],"to":[51,102,133,206],"review":[52],"the":[53,127],"role":[54],"apoC-III":[56,146,186],"angptl3":[58,188,196],"metabolism":[61,152],"combine":[63],"early":[64],"clinical":[65],"evidence":[66,183],"CVD":[68,160,210],"reducing":[69],"potential":[70],"new":[73],"targets.":[75],"RECENT":[76],"FINDINGS:":[77],"Angptl3":[78,144],"inhibition":[79,189,197],"by":[80,173],"mAb":[81],"antisense":[83,107],"therapy":[84,108],"has":[85],"recently":[86],"completed":[87],"phase":[88,139],"I":[89],"II":[91],"respectively":[93],"demonstrate":[95],"robust":[96],"apolipoprotein":[97],"B":[98],"(apoB)":[99],"lowering":[100],"up":[101],"46%.":[103],"Volanesorsen":[104],"is":[105],"an":[106],"approved":[109],"for":[110],"patients":[111],"with":[112],"extremely":[113],"elevated":[114],"plasma":[115],"levels":[117],"which":[119],"it":[120,202],"showed":[121,130],"no":[122],"consistent":[123],"apoB":[124,135,199],"reduction.":[125,212],"However,":[126],"GalNAc-conjugated":[128],"oligonucleotide":[129],"moderate":[131],"(up":[132],"\u223c30%)":[134],"reduction":[136,162,178],"a":[138],"1/2a":[140],"dose-finding":[141],"study.":[142],"SUMMARY:":[143],"are":[147],"targets":[149],"lipoprotein":[151,169],"that":[153,185],"triglycerides":[155],"when":[156],"inhibited.":[157],"The":[158],"expected":[159,205],"may":[163,203],"be":[164,204],"mediated":[165],"through":[166],"reduced":[167],"triglyceride-rich":[168],"particle":[170],"number,":[171],"reflected":[172],"apoB,":[174],"rather":[175],"than":[176],"per":[179],"se.":[180],"Limited":[181],"human":[182],"shows":[184],"both":[190],"potently":[191],"lower":[192],"triglycerides,":[193],"but":[194],"since":[195],"reduces":[198],"more":[200,208],"robustly":[201],"confer":[207],"favorable":[209]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W3019885136","counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":9},{"year":2022,"cited_by_count":9},{"year":2021,"cited_by_count":9},{"year":2020,"cited_by_count":4}],"updated_date":"2026-11-17T12:49:18.490984","created_date":"2020-05-01T00:00:00"}
